Genome Past Earnings Performance

Past criteria checks 0/6

Genome has been growing earnings at an average annual rate of 4.3%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 77.8% per year.

Key information

4.3%

Earnings growth rate

22.7%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate77.8%
Return on equity-43.8%
Net Margin-283.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

May 27
Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Apr 11
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Mar 08
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Mar 17
Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How Genome makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A314130 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2416,011-45,33429,12722,996
31 Dec 2314,296-47,46628,67725,666
30 Sep 2314,552-39,58121,37928,177
30 Jun 2314,987-42,68521,23031,242
31 Mar 2313,877-52,64220,99136,875
31 Dec 2214,085-51,83819,66436,793
30 Sep 2210,384-48,01120,00532,128
30 Jun 225,599-45,51317,47430,939
31 Mar 223,063-36,26814,92123,278
31 Dec 21451-34,11714,12321,263
30 Sep 21371-29,86011,82220,292
30 Jun 21308-45,18613,67616,728
31 Mar 21292-33,40613,53616,593
31 Dec 20151-30,73212,91513,669
31 Dec 1946-84,6695,9337,773

Quality Earnings: A314130 is currently unprofitable.

Growing Profit Margin: A314130 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A314130 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare A314130's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A314130 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).


Return on Equity

High ROE: A314130 has a negative Return on Equity (-43.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.